Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

MLAB vs PLUS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PLUS Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–3 Matrix Metrics)

PLUS Overall Winner 6-Pillar Tally: MLAB 3 – 3 PLUS Matrix Metrics: MLAB 3 – 6 PLUS

As of Nov 19, 2026, ePlus Inc (PLUS) is the stronger overall head-to-head candidate over Mesa Laboratories Inc (MLAB) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). MLAB carries a Unified Composite Score of 43.8/100 (HOLD) at $133.41 (24.8x Forward P/E, 10.4% operating margin), whereas PLUS carries 40.6/100 (SELL) at $95.64 (17.2x Forward P/E, 6.8% operating margin).

  • Composite vs. Pillar Nuance: While MLAB currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. PLUS 40.6/100 SELL), PLUS captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (6.8% vs. 10.4% operating margin) and revenue trajectory (+9.7% vs. +2.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MLAB vs PLUS
MLAB NASDAQ
Mesa Laboratories Inc
Industrial Instruments For Measurement, Display, And Control
$133.41
-3.19% 1D
Market Cap $774.6M
TTM Revenue $251M
Forward P/E 24.8x
Beta / 30D Vol 1.12β · 53% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.8% over 20 days), RSI 53
RSI-14: 52.5 · SMA20: $130.96 · SMA50: $129.90
PLUS NASDAQ Head-to-Head Winner
ePlus Inc
Wholesale-Computers & Peripheral Equipment & Software
$95.64
-1.35% 1D
Market Cap $2.5B
TTM Revenue $2.51B
Forward P/E 17.2x
Beta / 30D Vol 0.87β · 57% Vol
Unified Composite Score
40.6 / 100 SELL
Tech 13.0 Fund 39.0 Flow 54.0 Mom 36.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.8% over 20 days), RSI 53
RSI-14: 53.5 · SMA20: $94.02 · SMA50: $93.25

6-Pillar Scorecard Institutional Category Breakdown (MLAB 3 – 3 PLUS)

Columns: Metric · MLAB · PLUS
1. Valuation Multiples PLUS
Forward P/E 24.8x 17.2x
Trailing P/E 118.8x 20.3x
PEG Ratio N/M 1.11x
EV / Revenue 3.1x 0.9x
2. Growth & Scale PLUS
Revenue Growth (YoY) +2.6% +9.7%
Earnings Growth (YoY) +67.0% +18.0%
TTM Revenue (USD) $251M $2.51B
Market Cap $774.6M $2.5B
3. Profitability & Quality MLAB
Gross Margin 64.8% 25.2%
Operating Margin 10.4% 6.8%
Net Profit Margin 2.6% 5.0%
Return on Equity (ROE) 3.6% 11.6%
4. Balance Sheet & Cash Flow MLAB
Cash Generation (TTM) $49M EBITDA $32M
Cash Flow Margin 19.4% EBITDA Mgn 1.3%
Net Cash / Leverage $34.66 Book/Sh · 3.6% ROE $242M Net Cash
Dividend Yield 0.48% 1.09%
5. Options & Positioning PLUS
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 56.1% (26th %ile)
Put/Call OI Skew N/A 0.53x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat MLAB
OpEx & R&D Intensity 54.4% of Rev ($137M) 18.4% of Rev ($461M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Scientific & Technical Instruments Operator Software - Application Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MLAB (3) vs PLUS (6)
Institutional Metric MLAB PLUS Criterion Row Edge
Market Capitalization
Scale
$774.6M $2.5B Larger Scale PLUS
Trailing P/E Ratio
Valuation
118.8x 20.3x Lower Multiple PLUS
Forward P/E Ratio
Valuation
24.8x 17.2x Lower Multiple PLUS
Revenue Growth (YoY)
Growth
+2.6% +9.7% Higher Growth PLUS
Operating Margin (TTM)
Profitability
10.4% 6.8% Higher Margin MLAB
Net Profit Margin
Profitability
2.6% 5.0% Higher Margin PLUS
Return on Equity (ROE)
Capital Efficiency
3.6% 11.6% Higher ROE PLUS
52-Week Range Position
Momentum
85% ($70–$144) 85% ($73–$100) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.12β · 53% Vol 0.87β · 57% Vol Lower Realized Risk MLAB
Unified Institutional Score
Composite Signal
43.8 / 100 (HOLD) 40.6 / 100 (SELL) Higher Composite MLAB
Trailing 12M Revenue (USD)
Operating Scale
$251M $2.51B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.8% 25.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev 1.11x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$49M EBITDA ($34.66 Book/Sh · 3.6% ROE) $32M ($242M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MLAB +1.67 pp
MLAB: +3.26% · PLUS: +1.59%
3M Horizon PLUS +3.19 pp
MLAB: +6.93% · PLUS: +10.12%
6M Horizon MLAB +5.82 pp
MLAB: +22.27% · PLUS: +16.45%
1Y Horizon MLAB +80.57 pp
MLAB: +88.94% · PLUS: +8.37%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLAB vs PLUS. Trailing 12-month operating profitability (MLAB 10.4% vs PLUS 6.8%) and valuation multiples (MLAB 24.8x vs PLUS 17.2x Forward P/E) are benchmarked directly in Pillar 4 below.

MLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$251M
Gross Margin64.8%
Op. Margin10.4%
ROE / Fwd P/E3.6% · 24.8x
PLUS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.51B
Gross Margin25.2%
Op. Margin6.8%
ROE / Fwd P/E11.6% · 17.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PLUS CONSOLIDATION
135d in phase · OBV NEUTRAL
Current IV 56.1%
IV Percentile 26th %ile
Put/Call OI Skew 0.53x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact PLUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MLAB Moat Profile Cyclical / Execution-Driven Positioning
Scientific & Technical Instruments Operator
Competes within the Scientific & Technical Instruments value chain with $774.6M market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment 54.4% of Rev ($137M)
90D Engineering Disclosures 0 Published
PLUS Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $2.5B market capitalization and 6.8% operating margin.
OpEx & R&D Reinvestment 18.4% of Rev ($461M)
90D Engineering Disclosures 0 Published

Investor FAQ MLAB vs PLUS Key Questions & Quantitative Answers

As of Nov 19, 2026, ePlus Inc (PLUS) is the stronger overall head-to-head candidate over Mesa Laboratories Inc (MLAB) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). MLAB carries a Unified Composite Score of 43.8/100 (HOLD) at $133.41 (24.8x Forward P/E, 10.4% operating margin), whereas PLUS carries 40.6/100 (SELL) at $95.64 (17.2x Forward P/E, 6.8% operating margin). Composite vs. Pillar Nuance: While MLAB currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. PLUS 40.6/100 SELL), PLUS captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (6.8% vs. 10.4% operating margin) and revenue trajectory (+9.7% vs. +2.6% YoY).

PLUS leads the Growth & Scale pillar: MLAB posts +2.6% YoY revenue growth and +67.0% YoY earnings growth on $251M TTM revenue (64.8% gross margin, 10.4% operating margin), compared with PLUS at +9.7% YoY revenue growth and +18.0% YoY earnings growth on $2.51B TTM revenue (25.2% gross margin, 6.8% operating margin). On trailing 12-month operating scale, MLAB generates $251M in USD-normalized revenue versus $2.51B for PLUS. In operating R&D and SG&A reinvestment, MLAB deploys 54.4% of Rev ($137M) (0 90-day corporate R&D disclosures) versus 18.4% of Rev ($461M) (0 disclosures) for PLUS.

PLUS screens cheaper on headline valuation multiples. MLAB trades at 24.8x Forward P/E, 118.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (19.4% EBITDA margin), whereas PLUS trades at 17.2x Forward P/E, 20.3x Trailing P/E, 1.11x PEG, and 0.9x EV/Revenue (1.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLAB (3.6% ROE) versus PLUS (11.6% ROE) capital efficiency.

In options market volatility and institutional positioning, MLAB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.12β · 53% Vol realized risk). By comparison, PLUS carries 56.1% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.53x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.87β · 57% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.